BioSpace News Archive

Irvine, California-based Fluxergy LLC, a diagnostic test company, is making a $30 million investment to expand its capability to scale production of the Fluxergy Analyzer diagnostic testing system in response to the COVID-19 pandemic.

ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS or the Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced its operational and financial results for the three months ended March 31, 2020. “Over the course of the first quarter 2020, the value of our unique discovery a

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, will present data on its novel CD47 checkpoint inhibitor, TTI-622, at the Developmental Therapeutics Session of the ASCO20 Virtual Scientific Program to be held May 29-31, 2020. The presentation will highlight a first-in-human study evaluating TTI-622 in patients wi

Fulcrum Therapeutics, Inc. (Nasdaq: FULC) , a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today provided a business update and reported financial results for the first quarter of 2020. “Despite these unprecedented times, the first quarter was a period of important progress for Fulcrum and the fundamentals of our business remain strong,” said Robert J. Gould,

A new mail-in blood test for children with transplanted organs eliminates the need for vulnerable immunosuppressed patients to visit the hospital to have blood drawn in person.

Aleafia Health Inc. (TSX: ALEF, OTC: ALEAF, FRA: ARAH) (“Aleafia Health” or the “Company”), is pleased to report its financial results for the three months ended March 31, 2020 (“Q1 2020”).

GO2 Foundation for Lung Cancer (GO2 Foundation) has promoted Jennifer C. King, Ph.D., to the role of chief scientific officer.

Bruker Corporation announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.04 per share on the Company’s common stock.

Pear Therapeutics, Inc. , the leader in prescription digital therapeutics (PDTs), today announced that Corey McCann, M.D., Ph.D., President and CEO, will participate in a virtual panel discussion entitled “Emerging World of Digital Therapeutics” at the SVB Leerink CybeRx Series: Digital Health – Innovators & Disruptors on Thursday, May 21 at 12:35 p.m. Eastern Time. About Pear Therapeutics Pear

Bristol Myers Squibb to host an investor call today at 8:00 a.m. EDT bluebird bio to host an investor call today at 8:45 a.m. EDT